₹ 356.4
Key Takeaways
Risk factor
Resilient to price shocks
Profitability factor
Somewhat favourable analyst view
About
Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases. In addition, It is involved in the integrated discovery, development, and manufacturing services for small and...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is overpriced on P/E, of fair value o
Target Price
The average target price of BIOCON.NS is 382 and suggests 7% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendati
